-
Tytuł:
-
mRNA and miRNA Expression Analyses of the MYC / E2F /miR-17-92 Network in the Most Common Pediatric Brain Tumors.
-
Autorzy:
-
Gruszka R; Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Pomorska 251, 92-216 Lodz, Poland.; Biobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 139, 90-235 Lodz, Poland.
Zakrzewski K; Department of Neurosurgery, Polish Mother Memorial Hospital Research Institute in Lodz, Rzgowska 281/289, 93-338 Lodz, Poland.
Liberski PP; Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Pomorska 251, 92-216 Lodz, Poland.
Zakrzewska M; Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Pomorska 251, 92-216 Lodz, Poland.
-
Źródło:
-
International journal of molecular sciences [Int J Mol Sci] 2021 Jan 07; Vol. 22 (2). Date of Electronic Publication: 2021 Jan 07.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, Switzerland : MDPI, [2000-
-
MeSH Terms:
-
Astrocytoma/*genetics
Brain Neoplasms/*genetics
E2F Transcription Factors/*genetics
MicroRNAs/*genetics
Proto-Oncogene Proteins c-myc/*genetics
Astrocytoma/pathology ; Brain Neoplasms/pathology ; Carcinogenesis/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Gene Regulatory Networks/genetics ; Humans ; Pediatrics ; RNA, Long Noncoding ; RNA, Messenger/genetics
-
References:
-
J Biol Chem. 2007 Jan 26;282(4):2130-4. (PMID: 17135268)
J Mol Med (Berl). 2011 Oct;89(10):1037-50. (PMID: 21656380)
Int J Med Sci. 2018 Sep 7;15(13):1443-1448. (PMID: 30443163)
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2889-94. (PMID: 18287052)
Trends Mol Med. 2014 Aug;20(8):460-9. (PMID: 25027972)
J Mol Med (Berl). 2015 Oct;93(10):1075-84. (PMID: 26350064)
Nat Rev Cancer. 2019 Jun;19(6):326-338. (PMID: 31053804)
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14082-7. (PMID: 18779589)
Nat Genet. 2011 Sep 04;43(10):1026-30. (PMID: 21892160)
World Neurosurg. 2019 Jan;121:e519-e527. (PMID: 30268547)
Cancer Res. 2010 Nov 1;70(21):8547-57. (PMID: 20851997)
Nature. 2005 Feb 17;433(7027):769-73. (PMID: 15685193)
Cell Death Differ. 2013 Dec;20(12):1603-14. (PMID: 24212931)
Biomed Pharmacother. 2018 Nov;107:1705-1711. (PMID: 30257388)
Trends Biochem Sci. 2004 Aug;29(8):409-17. (PMID: 15362224)
Int J Mol Sci. 2020 Apr 27;21(9):. (PMID: 32349263)
Tumour Biol. 2016 Oct;37(10):14035-14048. (PMID: 27495233)
Int J Cancer. 2008 Feb 1;122(3):699-704. (PMID: 17943719)
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19678-83. (PMID: 19066217)
J Gastroenterol Hepatol. 2009 Apr;24(4):652-7. (PMID: 19175831)
Blood. 2007 May 15;109(10):4399-405. (PMID: 17284533)
PLoS One. 2015 Oct 14;10(10):e0140503. (PMID: 26465597)
FEBS Lett. 2018 Feb;592(3):446-458. (PMID: 29331028)
J Biomed Biotechnol. 2012;2012:970761. (PMID: 23226946)
Oncogenesis. 2014 Apr 21;3:e99. (PMID: 24752237)
Circ Res. 2013 Jun 7;112(12):1557-66. (PMID: 23575307)
Genes Dev. 2002 Oct 15;16(20):2699-712. (PMID: 12381668)
Oncogene. 1998 Aug 20;17(7):867-76. (PMID: 9780003)
Cancer Res. 2007 May 1;67(9):4005-9. (PMID: 17483310)
Folia Neuropathol. 2020;58(2):123-132. (PMID: 32729291)
Mol Cancer Res. 2014 Jun;12(6):815-22. (PMID: 24589438)
Surg Today. 2019 Sep;49(9):721-727. (PMID: 30848386)
Nature. 2002 Jan 24;415(6870):436-42. (PMID: 11807556)
Genes Dev. 2010 May 15;24(10):1059-72. (PMID: 20478998)
Genes Dev. 2000 Jun 1;14(11):1390-9. (PMID: 10837031)
World J Gastroenterol. 2014 May 28;20(20):5962-72. (PMID: 24876719)
Eur J Cancer. 2010 Jun;46(9):1640-9. (PMID: 20219352)
PLoS One. 2011;6(10):e25114. (PMID: 22053178)
Oncogene. 2007 Sep 6;26(41):6099-105. (PMID: 17384677)
J Biol Chem. 2007 Jan 26;282(4):2135-43. (PMID: 17135249)
PLoS One. 2011 Mar 03;6(3):e14742. (PMID: 21390222)
Nat Cell Biol. 2008 Apr;10(4):476-82. (PMID: 18364697)
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7331-6. (PMID: 12777630)
Acta Neuropathol. 2017 Sep;134(3):507-516. (PMID: 28401334)
Nature. 2005 Jun 9;435(7043):839-43. (PMID: 15944709)
Gastric Cancer. 2015 Apr;18(2):271-9. (PMID: 24626859)
Oncogene. 2014 Dec 4;33(49):5582-91. (PMID: 24317511)
Biochem Biophys Res Commun. 2016 Dec 9;481(3-4):245-250. (PMID: 27815074)
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1519-24. (PMID: 11171983)
Dev Biol. 2009 Sep 15;333(2):238-50. (PMID: 19559694)
Oncol Rep. 2013 Nov;30(5):2399-410. (PMID: 23970382)
Mol Oncol. 2014 Mar;8(2):417-30. (PMID: 24412053)
Breast Cancer Res Treat. 2011 Apr;126(3):565-75. (PMID: 20505989)
Oncotarget. 2017 Jul 22;8(39):65743-65758. (PMID: 29029468)
Mol Cell Biol. 2017 Oct 27;37(22):. (PMID: 28784723)
Int J Clin Exp Pathol. 2015 Jan 01;8(1):643-8. (PMID: 25755757)
J Transl Med. 2019 Oct 3;17(1):334. (PMID: 31581940)
J Mol Biol. 2004 May 28;339(2):327-35. (PMID: 15136036)
Br J Cancer. 2011 Nov 22;105(11):1733-40. (PMID: 22045190)
J Neuropathol Exp Neurol. 2019 Sep 1;78(9):791-797. (PMID: 31373367)
Genes (Basel). 2017 Mar 30;8(4):. (PMID: 28358317)
PLoS One. 2016 Jul 08;11(7):e0158464. (PMID: 27390862)
Exp Cell Res. 2014 May 15;324(1):54-64. (PMID: 24657544)
Cell. 2008 Apr 18;133(2):217-22. (PMID: 18423194)
-
Contributed Indexing:
-
Keywords: OncomiR-1; brain tumor; ependymoma; medulloblastoma; miR-106a-363; miR-106b-25; miR-17-92; microRNA; pilocytic astrocytoma
-
Substance Nomenclature:
-
0 (E2F Transcription Factors)
0 (MIR17HG, human)
0 (MIRN106 microRNA, human)
0 (MYC protein, human)
0 (MicroRNAs)
0 (Proto-Oncogene Proteins c-myc)
0 (RNA, Long Noncoding)
0 (RNA, Messenger)
-
Entry Date(s):
-
Date Created: 20210112 Date Completed: 20210330 Latest Revision: 20211204
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7827072
-
DOI:
-
10.3390/ijms22020543
-
PMID:
-
33430425
-
Numerous molecular factors disrupt the correctness of the cell cycle process leading to the development of cancer due to increased cell proliferation. Among known causative factors of such process is abnormal gene expression. Nowadays in the light of current knowledge such alterations are frequently considered in the context of mRNA-miRNA correlation. One of the molecular factors with potential value in tumorigenesis is the feedback loop between MYC and E2F genes in which miR-17-5p and miR-20a from the miR-17-92 cluster are involved. The current literature shows that overexpression of the members of the OncomiR-1 are involved in the development of many solid tumors. In the present work, we investigated the expression of components of the MYC / E2F /miR-17-92 network and their closely related elements including members of MYC and E2F families and miRNAs from two paralogs of miR-17-92: miR-106b-25 and miR-106a-363, in the most common brain tumors of childhood, pilocytic astrocytoma (PA), WHO grade 1; ependymoma (EP), WHO grade 2; and medulloblastoma (MB), WHO grade 4. We showed that the highest gene expression was observed in the MYC family for MYCN and in the E2F family for E2F2 . Positive correlation was observed between the gene expression and tumor grade and type, with the highest expression being noted for medulloblastomas, followed by ependymomas, and the lowest for pilocytic astrocytomas. Most members of miR-17-92, miR-106a-363 and miR-106b-25 clusters were upregulated and the highest expression was noted for miR-18a and miR-18b. The rest of the miRNAs, including miR-19a, miR-92a, miR-106a, miR-93, or miR-25 also showed high values. miR-17-5p, miR-20a obtained a high level of expression in medulloblastomas and ependymomas, while close to the control in the pilocytic astrocytoma samples. miRNA expression also depended on tumor grade and histology.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.